Designer heparinoids by Heparinex, fine-tuned size and structural control

Innovative Biopharmaceutical Compound Synthesis

Heparinex, L.L.C. is a biopharmaceutical company focused on the novel recombinant synthesis of compounds for markets including anticoagulation, inflammation, and cancer treatment areas. Leading carbohydrate chemist and glycobiologist Dr. Paul DeAngelis, originally discovered and patented Heparinex’s core technology platforms of proprietary carbohydrate production.

Heparinex’s Core Platforms Employ

  • Bacterial production techniques
  • In vitro defined, enzyme-catalyzed polymer syntheses to provide uniquely controlled non-animal sources of heparinoid compounds for biotherapeutic, tissue engineering, and medical device applications

Technology

Heparinex was founded upon the discovery of two novel methodologies to produce synthetic heparinoid compounds in a highly controlled manner. Heparin is used as an anticoagulant and antithrombotic agent in a wide variety of medical conditions. Traditional production techniques involve procuring and purifying heparin from sources such as porcine intestine and bovine lung. While the current methods are adequate, they limit the potential applications of heparin due to the inherent variability in the molecular size and weight of the heparin chains. The Heparinex solution circumvents these issues by providing techniques to produce uniform monodisperse heparin chains.

Carbohydrate Expertise

Dr. Paul L. DeAngelis serves as the Chief Scientist of Heparinex. Dr. DeAngelis is a recognized leader in the glycobiology field and has been directly involved in commercializing technologies associated with heparin, chondroitin, and hyaluronic acid developed in his laboratories. As an undergraduate at Harvard (B.A. 1984), Dr. DeAngelis investigated the carbohydrate structures of polysaccharides from fungal pathogens that their plant hosts detected as “foreign” by creating and testing a series of synthetic structural mimics. As a graduate student at the University of California, Irvine (Ph.D. 1990), he elucidated unique details surrounding fertilization, such as defining the critical elements of egg surface polysaccharides and the essential residues of a sperm adhesive protein.

As a postdoctoral researcher (1990-93) in the laboratory of Dr. Paul Weigel at the University of Texas Medical Branch, Galveston, Dr. DeAngelis identified the first hyaluronan synthase to be described from the human bacterial pathogen Group A Streptococcus. Currently, as a Professor at the University of Oklahoma Health Sciences Center in Oklahoma City, he directs a laboratory exploring various aspects of prokaryotic and eukaryotic polysaccharide biosynthesis. Discoveries from 1997 to 2003 include the identification of two more unique hyaluronan synthases and the first chondroitin and heparin synthase.

For more information CLICK HERE.

Glycosaminoglycan (GAG) Experience

Heparinex is managed by life sciences management and venture firm Emergent Technologies, Inc. (ETI). Over the course of nearly 20 years, ETI has acquired extensive experience and expertise in the evolving carbohydrate research development field and currently manages and directs two unique glyco aminoglycan portfolio companies, Heparinex and Hyalose, LLC. Collectively, ETI and its portfolio companies have patents covering unique synthesis techniques for carbohydrate compounds such as heparin and hyaluronic acid and associated chimeric derivatives. ETI leverages this expertise across multiple industrial and general consumer application arenas and is positioned to serve as an international carbohydrate innovation clearinghouse.


To learn more visit:

Applications

Commercial Applications in Multiple High-Yield Industries

Heparinex’s proprietary carbohydrate production platform technologies provide applications for multiple high-yield industries including:
  • Anticoagulants
  • Medical device coatings
  • Reconstructive surgery
  • Novel autoimmune/infectious disease/cancer drug discovery
  • Heparosan-Based Drug Delivery System Technology for licensing in the drug half-life extension and/or pharmacokinetic enhancer fields

To learn more visit:

Contact Us

Heparinex L.L.C.

Business Operations:

c/o Emergent Technologies, Inc.
7500 Rialto Blvd., Bldg. 2 Ste. 260
Austin, TX 78735

Technical Contact:

Dr. Paul DeAngelis, Chief Scientist
Oklahoma City, OK USA 73104

Phone: (405) 271-2227 x61210

Copyright © 2019 Heparinex L.L.C. All rights reserved.

Website designed by RTL Digital Media